Eris Q2 FY27 slides: profit surges 39% on diabetes strength

Eris Lifesciences reported a 39.2% year-over-year surge in profit after tax (PAT) during Q2 FY27, reaching ₹187 crore. The company's revenue grew 12.6% to ₹892 crore. Despite strong performance, the stock traded near its 52-week low, closing at ₹1,100 with a 0.41% gain. Analysts view the stock as potentially undervalued. The company's strategy and operations played a crucial role in this growth, with EBITDA reaching ₹309 crore in Q2, up 7.3% from the previous year.

The DBF segment, the core of Eris's business, experienced 14.1% year-over-year revenue growth, with organic growth accelerating to 16.5% when excluding the Zorvia licensing deal. The company's focus on chronic and sub-chronic therapies provides stability. A licensing agreement with Zorvia Healthcare is expected to drive margin improvements.

Eris's diabetes portfolio is a major competitive differentiator, with Q2 FY27 revenue growing 18.5%, outpacing the overall Indian pharmaceutical market's growth by 240 basis points. The company is also advancing in its diabetes pipeline, with regulatory approval granted for Phase 1 and Phase 3 clinical trials of India's first recombinant semaglutide.